YK

Yatin Kirtanlal Desai

Active Director Director DIN 00030719
DIN 00030719 First appointment Dec 1993 Primary industry Research & Development
Unlock full profile Investments · shareholding · contact details
Current companies 2 active board seats
Past companies 5 historical roles
Total affiliations 7 Since Dec 1993
Shareholding value •••• Premium profile

About Yatin Kirtanlal Desai

Data last updated:

Yatin Kirtanlal Desai is a Director at Difgen Pharmaceuticals Private Limited (since 2022) and Director at Orizo Pharma Private Limited (since 2023). The companies operate in Research & Development, Pharma and Food And Beverages. The largest current company by reported revenue is Difgen Pharmaceuticals Private Limited at ₹76.63 Cr (FY 2025). Earlier, Yatin Kirtanlal Desai was a Director at Stonefish Management Services Private Limited (2009–2015) and Director at Shree Maa Pharmachem Limited (2007–2008) and 3 more.

DIN 00030719
Primary Designation Director
Industry Research & Development
First Appointment 23 Dec 1993
Oldest Company Age 32 yrs
Largest company Difgen Pharmaceuticals Private Limited · ₹76.63 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 May 20222022₹76.63 Cr (FY 2025)Active
Orizo Pharma Private Limited U24290TG2022PTC158573
Director24 May 20232022Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Jan 20092009Active
Shree Maa Pharmachem Limited U24230MH2005PLC151414
Director12 Mar 20072005Under Liquidation
Lucerne Developers Private Limited U45203MH2010PTC208644
Director07 Oct 20102010Strike Off
Trufin Consultancy Private Limited U74140MH1993PTC075754
Director23 Dec 19931993Converted To Llp
Designated Partner21 Feb 20152015Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Difgen Pharmaceuticals Private Limited
Orizo Pharma Private Limited
Lucerne Developers Private Limited
Trufin Consultancy Private Limited
Premium access

Shareholding and investment profile for Yatin Kirtanlal Desai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Yatin Kirtanlal Desai

Yatin Kirtanlal Desai currently holds 2 directorships: Difgen Pharmaceuticals Private Limited (Director, since 24 May 2022, revenue ₹76.63 Cr (FY 2025)); Orizo Pharma Private Limited (Director, since 24 May 2023).

Yatin Kirtanlal Desai was first appointed on 23 Dec 1993 as Director at Trufin Consultancy Private Limited. The most recent appointment on record is 24 May 2023 at Orizo Pharma Private Limited.

Yatin Kirtanlal Desai held 5 earlier board appointments: Stonefish Management Services Private Limited (Director, 05 Jan 2009 to 26 Mar 2015); Shree Maa Pharmachem Limited (Director, 12 Mar 2007 to 01 Aug 2008); Lucerne Developers Private Limited (Director, from 07 Oct 2010); Trufin Consultancy Private Limited (Director, from 23 Dec 1993); B Y & Associates Limited Liability Partnership (Designated Partner, from 21 Feb 2015).

The current boards of Yatin Kirtanlal Desai's companies include Amol Ashok Walke (Difgen Pharmaceuticals Private Limited), Krishna Chandrasekaran (Difgen Pharmaceuticals Private Limited), Narasimhan Sridhar Nagaarjun (Difgen Pharmaceuticals Private Limited), Punit Chunilal Thakrar (Difgen Pharmaceuticals Private Limited), Ramandeep Singh Jaj (Difgen Pharmaceuticals Private Limited), Santhanakrishnan Srinivasan (Difgen Pharmaceuticals Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available